Similar treatment advantage was also revealed in patients with esophageal cancer in the KEYNOTE-181 study, (63% of patients with squamous cell histology) in which RR, PFS, and OS all increased with pembrolizumab compared to chemotherapy in patients with PD-L1 expression of at least 10 (24). The gene discussed is CD274; the disease is esophageal cancer.